HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis

  • Ribeiro A
  • Bocca A
  • Amaral A
 et al. 
  • 13


    Mendeley users who have this article in their library.
  • 19


    Citations of this article.


The conventional treatment for paracoccidioidomycosis, the most prevalent mycosis in Latin America, involves long periods of therapy resulting in sequels and high frequency of relapses. The search for new alternatives of treatment is necessary. Previously, we have demonstrated that the hsp65 gene from Mycobacterium leprae shows prophylactic effects against murine paracoccidioidomycosis. Here, we tested the DNAhsp65 immunotherapy in BALB/c mice infected with Paracoccidioides brasiliensis, the agent of paracoccidioidomycosis. We observed an increase of Th1 cytokines accompanied by a reduction in fungal burden and pulmonary injury. These results provide new prospects for immunotherapy of paracoccidioidomycosis and other mycoses. © 2009 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • DNAhsp65
  • Immunotherapy
  • Paracoccidioidomycosis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free